3 results match your criteria: "Medical Services and Clinical Development[Affiliation]"
Cureus
May 2024
Medical Services and Clinical Development, Himalaya Wellness Company, Bengaluru, IND.
Background The hepatoprotective function of polyherbal formulation Liv.52 in chronic liver diseases is well recognized in published literature. The objective of this open-label, phase IV study was to further strengthen and validate its safety and effectiveness using a large patient pool in a real-world scenario and provide scientific data on symptomatic improvement and supportive treatment in liver function with improvement in quality of life.
View Article and Find Full Text PDFJ Cancer Res Ther
February 2022
Principal Scientist-Medical Services and Clinical Development, The Himalaya Drug Company, Bengaluru, Karnataka, India.
Introduction: Oral mucositis is inflammation of the mucosa of the mouth which ranges from redness to severe ulceration. It results from the local effects of radiation to the oral mucosa.
Objectives: The study is cumulative analysis of two studies (one comparative and the other open labeled) evaluated in individuals with oral mucositis during cancer radiotherapy and/or chemotherapy for the safety and efficacy of Oro-T mouthwash in a comparative design with normal saline.
J Cosmet Dermatol
July 2022
Medical Services and Clinical Development, The Himalaya Drug Company, Bengaluru, India.
Background: Acne vulgaris is a chronic, inflammatory skin condition of pilosebaceous units. The standard treatment involves topical and oral antibiotics, retinoids, benzoyl peroxide, and other synthetic compounds, mostly associated with adverse effects. Hence, herbal skincare products are considered nowadays.
View Article and Find Full Text PDF